EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Liver Stiffness Measurements After Oral Antivirals Effectively Predict the Risk of HCC in Patients With Chronic Hepatitis C

Yu Rim Lee iD, Hyun Young Woo, Young Oh Kweon, Won Young Tak iD, Se Young Jang, Jung Gil Park, Min Kyu Kang iD, Jeong Eun Song iD, Byoung Kuk Jang, Changhyeong Lee, Byung Seok Kim, Jae Seok Hwang und 10 weitere

Journal of Gastroenterology and Hepatology · 2025

DOI: 10.1111/jgh.70064 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2025. Verfasst von Yu Rim Lee und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, South Kore…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Antiviral Agents, Liver Neoplasms, Hepatitis C, Chronic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Hepatocellular carcinoma (HCC) can still occur in patients with chronic hepatitis C after achieving a sustained virologic response (SVR) with direct‐acting antiviral (DAA) therapy. Therefore, we aimed to identify and validate predictors and HCC risk models using longitudinal data.

Method

This retrospective cohort study included patients who achieved SVR after DAA therapy. Model performance was assessed using Harrell's C‐index and the area under the time‐dependent receiver operating characteristic curve (AUROC).

Results

After excluding patients who developed HCC or died within 1 year after achieving SVR, a total of 2778 patients were finally included in this study. 154 (5.5%) patients developed HCC at a median of 3.3 years. LSM value showed significant improvement after antiviral therapy (all p < 0.05). In the multivariable analysis, LSM at baseline and 1 year after SVR were significantly associated with the occurrence of HCC (all p < 0.05). LSM at 1 year after SVR could better predict HCC risk than baseline LSM (C‐index: 0.760, 0.788 at baseline, 1 year after SVR, respectively). Low‐risk patients (LSM < 10 kPa) using LSM values at 1 year after SVR (76.4%) showed an incidence risk of 0.482 incidence rate/100 patient‐years. In patients with advanced chronic liver disease, LSM at 1 year after SVR demonstrated superior predictive performance for HCC development compared to baseline LSM and other prediction models assessed at various time points (C‐index: 0.744, 95% CI: 0.660–0.829; 3‐year follow‐up AUROC: 0.794, 95% CI: 0.754–0.831).

Conclusions

LSM after achieving SVR effectively predicts HCC risk, especially in patients with advanced chronic liver disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularAntiviral AgentsLiver NeoplasmsHepatitis C, ChronicLiverElasticity Imaging TechniquesHumansMaleFemaleMiddle AgedRetrospective StudiesSustained Virologic ResponseAdministration, OralAgedRisk AssessmentPredictive Value of TestsRisk FactorsAdultCohort Studies

Stichwörter der Autor:innen

hepatitis C virushepatocellular carcinomaliver stiffnessrisk scoresustained virological response (SVR)

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Department of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, South Korea.
  • Department of Internal Medicine, College of Medicine, Pusan National University and Medical Research Institute, Pusan National University Hospital, Busan, South Korea.
  • Department of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, South Korea.
  • Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, South Korea.
  • Department of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, South Korea.
  • Department of Internal Medicine, Keimyung University School of Medicine, Daegu, South Korea.

ORCID-Profile: Yu Rim Lee, Won Young Tak, Min Kyu Kang, Jeong Eun Song, Nae-Yun Heo, Seung Ha Park, Soo Young Park

Zitieren

APA

Lee, Y. R., Woo, H. Y., Kweon, Y. O., Tak, W. Y., Jang, S. Y., Park, J. G., Kang, M. K., Song, J. E., Jang, B. K., Lee, C., Kim, B. S., Hwang, J. S., Chung, W. J., Heo, J., Heo, N. Y., Park, S. H., Yoon, J. S., Jeong, J., Kwak, S. G., …, & Park, S. Y. (2025). Liver Stiffness Measurements After Oral Antivirals Effectively Predict the Risk of HCC in Patients With Chronic Hepatitis C. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.70064

Vancouver

Lee YR, Woo HY, Kweon YO, Tak WY, Jang SY, Park JG, et al. Liver Stiffness Measurements After Oral Antivirals Effectively Predict the Risk of HCC in Patients With Chronic Hepatitis C. Journal of Gastroenterology and Hepatology. 2025. doi:10.1111/jgh.70064

BibTeX
@article{Lee2025,
  author = {Lee, Yu Rim and Woo, Hyun Young and Kweon, Young Oh and Tak, Won Young and Jang, Se Young and Park, Jung Gil and Kang, Min Kyu and Song, Jeong Eun and Jang, Byoung Kuk and Lee, Changhyeong and Kim, Byung Seok and Hwang, Jae Seok and Chung, Woo Jin and Heo, Jeong and Heo, Nae-Yun and Park, Seung Ha and Yoon, Jun Sik and Jeong, Joonho and Kwak, Sang Gyu and Kang, Yeowool and Baek, Yang Hyun and Park, Soo Young},
  title = {Liver Stiffness Measurements After Oral Antivirals Effectively Predict the Risk of HCC in Patients With Chronic Hepatitis C},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2025},
  doi = {10.1111/jgh.70064}
}
Kostenlos starten →